6 Participants Needed

Ga-68-DOTATATE vs. Ga-68-DOTATOC PET Scans for Meningioma

JI
GM
EC
Overseen ByEileen Chang
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Weill Medical College of Cornell University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the drug Ga-68-DOTATATE for meningioma?

Research shows that Ga-68-DOTATATE PET scans can help in detecting and planning treatment for meningiomas, especially when combined with MRI, leading to better identification of tumor areas and more precise radiation treatment. This drug has been found to be more sensitive and specific than MRI alone, aiding in the detection of recurrent meningioma and improving treatment outcomes.12345

Is Ga-68-DOTATATE or Ga-68-DOTATOC safe for use in humans?

The studies reviewed focus on the use of Ga-68-DOTATATE and Ga-68-DOTATOC for imaging in meningioma treatment planning, but they do not provide specific safety data. However, these agents are commonly used in medical imaging, suggesting they are generally considered safe for human use.12467

How is the treatment with Ga-68-DOTATATE and Ga-68-DOTATOC different from other treatments for meningioma?

Ga-68-DOTATATE and Ga-68-DOTATOC are unique because they are used in PET scans to better visualize meningiomas by targeting somatostatin receptors, which are often present in these tumors. This approach helps in more precise radiation treatment planning compared to traditional MRI, potentially leading to smaller radiation volumes and improved detection of tumor areas.12348

What is the purpose of this trial?

This trial is evaluating different imaging scans to determine which one is more effective in detecting brain tumors in patients with meningioma. The scans use substances that make the tumors more visible, aiding doctors in their diagnosis.

Research Team

JI

Jana Ivanidze, MD/PhD

Principal Investigator

Weill Medical College of Cornell University

Eligibility Criteria

This trial is for adults who are suspected to have meningioma and are preparing for surgery. They must be able to lie still on a scanner table and not have any reasons they can't receive the radiotracers being tested.

Inclusion Criteria

I am preparing for surgery with necessary pre-surgery evaluations.
I am an adult suspected to have meningioma.
I have no known allergies or reactions to diagnostic dyes or tracers.

Exclusion Criteria

I am under 18 years old.
I cannot lay on a scanner table for long due to pain or claustrophobia.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging Comparison

Direct comparison of Ga-68-DOTATATE and Ga-68-DOTATOC PET/CT in patients with meningioma

12 months
Multiple imaging sessions

Surgical Resection and Biomarker Analysis

Patients undergo surgical resection of the lesion and biomarker analysis is performed

12 months

Follow-up

Participants are monitored for safety and effectiveness after imaging and surgical procedures

4 weeks

Treatment Details

Interventions

  • Ga-68-DOTATATE
  • Ga-68-DOTATOC
Trial Overview The study aims to directly compare two imaging agents, Ga-68-DOTATATE and Ga-68-DOTATOC, using PET/CT or PET/MR scans in patients with meningioma to see which provides better information.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Patients with MeningiomaExperimental Treatment2 Interventions
Subjects with suspected meningioma planned for surgery who meet the inclusion and exclusion criteria.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Weill Medical College of Cornell University

Lead Sponsor

Trials
1,103
Recruited
1,157,000+

Cornell University

Collaborator

Trials
179
Recruited
14,090,000+

References

Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. [2021]
The Prognostic Value of Pretreatment Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography in Irradiated Non-benign Meningioma. [2022]
The Complementary Role of 68Ga-DOTATATE PET/CT in Diagnosis of Recurrent Meningioma. [2022]
68Ga-DOTATATE PET-Based Radiation Contouring Creates More Precise Radiation Volumes for Patients With Meningioma. [2022]
Improved Detection of Postoperative Residual Meningioma with [68Ga]Ga-DOTA-TOC PET Imaging Using a High-resolution Research Tomograph PET Scanner. [2022]
A Prospective Registry Study of 68Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial Meningiomas. [2023]
Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI. [2021]
Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security